Alejandro Checa, Eliana Navas, V. Valencia, Jessica Alcívar
{"title":"Cognitive impairment in people with COVID-19 with mild-moderate symptoms in Ecuador","authors":"Alejandro Checa, Eliana Navas, V. Valencia, Jessica Alcívar","doi":"10.24875/rmn.21000060","DOIUrl":null,"url":null,"abstract":"Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. (English) [ FROM AUTHOR] Antecedentes: Las complicaciones de COVID-19 pueden incluir secuelas neurológicas, psiquiátricas, psicológicas y psicosociales. Se sabe poco sobre las consecuencias del COVID-19 en las funciones cognitivas de los pacientes en la fase subaguda de la enfermedad. Objetivo: Determinar si existe incidencia de deterioro cognitivo en pacientes con COVID-19 con síntomas leves a moderados en la fase de remisión. Método: Se trata de un estudio de tipo transversal realizado entre abril de 2021 y agosto de 2021 en el Hospital Eugenio Espejo de Quito, Ecuador. Se aplicó el MoCA test a los pacientes con COVID-19 con síntomas de leve a moderado. Resultados: Un total de 50 sujetos fueron reclutados, el 88% (n = 44) presentó deterioro cognitivo y apenas el 12% (n = 6) evidenció una puntuación normal. Conclusiones: En nuestro estudio de cohorte los pacientes con COVID-19 con sintomatología leve-moderada tienen un alto riesgo de presentar deterioro cognitivo. (Spanish) [ FROM AUTHOR] Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Mexicana de Neurociencia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/rmn.21000060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. (English) [ FROM AUTHOR] Antecedentes: Las complicaciones de COVID-19 pueden incluir secuelas neurológicas, psiquiátricas, psicológicas y psicosociales. Se sabe poco sobre las consecuencias del COVID-19 en las funciones cognitivas de los pacientes en la fase subaguda de la enfermedad. Objetivo: Determinar si existe incidencia de deterioro cognitivo en pacientes con COVID-19 con síntomas leves a moderados en la fase de remisión. Método: Se trata de un estudio de tipo transversal realizado entre abril de 2021 y agosto de 2021 en el Hospital Eugenio Espejo de Quito, Ecuador. Se aplicó el MoCA test a los pacientes con COVID-19 con síntomas de leve a moderado. Resultados: Un total de 50 sujetos fueron reclutados, el 88% (n = 44) presentó deterioro cognitivo y apenas el 12% (n = 6) evidenció una puntuación normal. Conclusiones: En nuestro estudio de cohorte los pacientes con COVID-19 con sintomatología leve-moderada tienen un alto riesgo de presentar deterioro cognitivo. (Spanish) [ FROM AUTHOR] Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)